Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The U.S. Food and Drug Administration (FDA) has delayed the full approval of Novavax’s COVID-19 vaccine.  The decision had ...

Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...